Not yet medically reviewed, information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Stimulant / Amphetamine
Stimulant

Amphetamine

1-phenylpropan-2-amine

Amphetamine (e.g., Adderall) is a prescription stimulant for ADHD and narcolepsy; misuse strains the heart, can cause dependence and psychosis, and is dangerous combined with other drugs.

Overview

Amphetamine is a prescription stimulant, most familiar as the mixed amphetamine salts sold under the brand name Adderall, used to treat attention-deficit/hyperactivity disorder (ADHD), narcolepsy, and (in some formulations) binge-eating disorder. Taken as prescribed under medical supervision it can improve attention and reduce impulsivity and hyperactivity, but it is a controlled substance with a recognized potential for misuse, dependence, and addiction. Misuse — taking more than prescribed, using it without a prescription (for example to study or stay awake), or taking it by routes other than swallowing — raises the risks substantially. Regulators have strengthened warnings about the serious risks of prescription stimulants, including misuse, addiction, overdose, and death.

Source: NIDA; FDA; DEA

Chemistry & mechanism of action

Amphetamine increases the activity of the neurotransmitters dopamine and norepinephrine in the brain, boosting alertness, attention, and energy and, at higher doses, producing euphoria that can reinforce repeated use. The same stimulation activates the cardiovascular system, raising heart rate and blood pressure. In people with ADHD, carefully dosed stimulant medication can improve focus; at higher or misused doses the same mechanisms drive the drug's dangers — cardiovascular strain, agitation, and, with heavy use, disruption of normal dopamine signaling that can affect mood and behavior. With repeated misuse, tolerance and dependence can develop.

Source: NIDA; PubChem CID 3007

Effects

At therapeutic doses, amphetamine improves attention and wakefulness and can suppress appetite. Common effects, especially at higher or misused doses, include increased energy and alertness, euphoria, talkativeness, reduced appetite, insomnia, dry mouth, and a faster heartbeat. As the dose rises, effects can include anxiety, restlessness, irritability, raised blood pressure, and — at high doses or with heavy use — paranoia, hallucinations, and stimulant psychosis. Coming down can bring fatigue, low mood, and difficulty concentrating. Long-term misuse is associated with cardiovascular problems, weight loss, sleep disruption, and mental-health effects.

Source: NIDA; FDA

Risks & harms

The main acute danger is cardiovascular: amphetamine raises heart rate and blood pressure and can, particularly at high doses or in people with underlying heart conditions, contribute to dangerously high blood pressure, irregular heart rhythms, heart attack, stroke, seizures, or dangerously high body temperature. Unlike opioids, there is no reversal medication for a stimulant overdose — emergency care is the response, so chest pain, severe agitation, very high temperature, or seizures mean calling 911. Combining amphetamine with other stimulants (including cocaine or large amounts of caffeine) compounds cardiovascular strain, and combining it with opioids or other depressants is dangerous because the stimulant can mask sedation and lead to taking more of the depressant. Heavy or high-dose use can trigger stimulant psychosis. Misuse can lead to dependence, and any pill obtained outside a licensed pharmacy can be a counterfeit containing other substances, including fentanyl, so naloxone is worth having on hand. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.

Source: NIDA; FDA; SAMHSA

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With stimulants, overheating and a racing heart are the main concerns, get somewhere cool, stop any physical activity, and don't take more.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown, pending review”

Identity

IUPAC name
1-phenylpropan-2-aminePubChem PUG-REST ↗ · retrieved 2026-06-18
InChIKey
KWTSXDURSIMDCE-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
Synonyms / aliases
speed, Amfetamine, 1-phenylpropan-2-amine, dl-Amphetamine, 1-Phenyl-2-aminopropane, Desoxynorephedrine, Norephedrane, Elastonon, Fenopromin, Phenedrine, beta-AminopropylbenzenePubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Dosage form
HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
Shape
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Color
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Imprint
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Score
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)

Scheduling & legal status

US schedule
Unknown — pending review
International
Unknown, pending review

Effects, risks & interactions

Effects
Amphetamine is a stimulant that increases the release of the neurotransmitters dopamine and noradrenaline. In medicine it treats ADHD and narcolepsy; its effects include heightened alertness, wakefulness, focus and energy, reduced appetite, and often a sense of confidence or, at higher exposure, euphoria. As a sympathomimetic it also raises heart rate and blood pressure. Where a therapeutic effect ends and a harmful one begins is largely a matter of dose and context.PubChem CID 3007 + DailyMed label ↗ · retrieved 2026-06-18
Risks
Amphetamine's foremost risks are cardiovascular: it pushes heart rate and blood pressure higher and, especially at high doses or in people with underlying heart disease, can contribute to arrhythmia, heart attack and stroke — sudden death has been reported in people with structural cardiac abnormalities. It can also drive dangerous overheating (hyperthermia). At high or chronic doses it can produce a stimulant psychosis — paranoia, hallucinations and agitation resembling a psychotic episode. Repeated use brings tolerance and dependence, followed by a depleted, low-mood "crash" and withdrawal on stopping.PubChem CID 3007 + DailyMed label ↗ · retrieved 2026-06-18
Interactions
Amphetamine's labelling warns most strongly against monoamine-oxidase inhibitors (MAOIs): pairing a CNS stimulant with an MAOI can trigger a hypertensive crisis whose potential outcomes include stroke, heart attack and death, so the two must never be combined — nor amphetamine used within two weeks of stopping an MAOI. The label also notes that agents which alkalinize the gut or urine push amphetamine blood levels up while acidifying agents pull them down, and that amphetamine can blunt the effect of some blood-pressure medicines.DailyMed §7 Drug Interactions ↗ · retrieved 2026-06-18

Pill catalog

Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending review

This drug comes in 300different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.

Showing 24 of 300 variants

M Amphet S
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
M Amphet Salts 10 mg
Color
BLUE
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
Sandoz Inc
Schedule
CII
NDC
0781-2335 ↗ · 2026-06-18
N31
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
N31
Color
BLUE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-192 ↗ · 2026-06-18
?
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
Unknown — pending review
Color
Unknown — pending review
Shape
Unknown — pending review
Form
TABLET
Labeler
Bryant Ranch Prepack
Schedule
CII
NDC
71335-1249 ↗ · 2026-06-18
N29
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
Imprint
N29
Color
BLUE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-190 ↗ · 2026-06-18
N30
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 1.875 mg/1; AMPHETAMINE SULFATE 1.875 mg/1; DE
Imprint
N30
Color
BLUE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-191 ↗ · 2026-06-18
E 111
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
E 111
Color
BLUE
Shape
ROUND
Form
TABLET
Labeler
Sandoz Inc
Schedule
CII
NDC
0185-0842 ↗ · 2026-06-18
?
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTROAMPHETAMINE
Imprint
Unknown — pending review
Color
Unknown — pending review
Shape
Unknown — pending review
Form
TABLET
Labeler
Bryant Ranch Prepack
Schedule
CII
NDC
71335-0171 ↗ · 2026-06-18
AMG 277
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE DL-ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; D
Imprint
AMG 277
Color
GREEN
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
ANI Pharmaceuticals, Inc.
Schedule
CII
NDC
43975-277 ↗ · 2026-06-18
30 mgM 895
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1; DEXTRO
Imprint
30 mgM 8956
Color
orange
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
SpecGx LLC
Schedule
CII
NDC
0406-8956 ↗ · 2026-06-18
N32
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1; DE
Imprint
N32
Color
ORANGE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-193 ↗ · 2026-06-18
?
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; DEXT
Imprint
Unknown — pending review
Color
Unknown — pending review
Shape
Unknown — pending review
Form
CAPSULE, EXTENDED RELEASE
Labeler
Lannett Company, Inc.
Schedule
CII
NDC
0527-0794 ↗ · 2026-06-18
N33
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 3.75 mg/1; AMPHETAMINE SULFATE 3.75 mg/1; DEXT
Imprint
N33
Color
ORANGE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-194 ↗ · 2026-06-18
N34
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROAMPH
Imprint
N34
Color
ORANGE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-195 ↗ · 2026-06-18
AMG 281
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE DL-ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; D
Imprint
AMG 281
Color
PINK
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
ANI Pharmaceuticals, Inc.
Schedule
CII
NDC
43975-281 ↗ · 2026-06-18
Lannett 07
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROAMPH
Imprint
Lannett 0793
Color
orange
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
Golden State Medical Supply, Inc.
Schedule
CII
NDC
51407-560 ↗ · 2026-06-18
G10 113
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
G10 113
Color
white
Shape
OVAL
Form
TABLET
Labeler
Granules Pharmaceuticals Inc.
Schedule
CII
NDC
70010-113 ↗ · 2026-06-18
N35
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1; DEXTRO
Imprint
N35
Color
ORANGE
Shape
ROUND
Form
TABLET
Labeler
SUNRISE PHARMACEUTICAL, INC.
Schedule
CII
NDC
11534-196 ↗ · 2026-06-18
AMG 278
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE DL-ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEX
Imprint
AMG 278
Color
GREEN
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
ANI Pharmaceuticals, Inc.
Schedule
CII
NDC
43975-278 ↗ · 2026-06-18
LANNETT 07
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
Imprint
LANNETT 0790
Color
white
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
Golden State Medical Supply, Inc.
Schedule
CII
NDC
51407-557 ↗ · 2026-06-18
G5 111
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
Imprint
G5 111
Color
white
Shape
OVAL
Form
TABLET
Labeler
Granules Pharmaceuticals Inc.
Schedule
CII
NDC
70010-111 ↗ · 2026-06-18
AMG 279
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE DL-ASPARTATE MONOHYDRATE 3.75 mg/1; AMPHETAMINE SULFATE 3.75 mg/1; D
Imprint
AMG 279
Color
GREEN
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
ANI Pharmaceuticals, Inc.
Schedule
CII
NDC
43975-279 ↗ · 2026-06-18
Lannett 07
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
Imprint
Lannett 0791
Color
blue
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
Golden State Medical Supply, Inc.
Schedule
CII
NDC
51407-558 ↗ · 2026-06-18
G7 5 112
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE ASPARTATE MONOHYDRATE 1.875 mg/1; AMPHETAMINE SULFATE 1.875 mg/1; DE
Imprint
G7 5 112
Color
white
Shape
ROUND
Form
TABLET
Labeler
Granules Pharmaceuticals Inc.
Schedule
CII
NDC
70010-112 ↗ · 2026-06-18
AMG 280
Illustration based on reported characteristics. Appearance varies, identical-looking pills can contain completely different substances. Always test.
Strength
AMPHETAMINE DL-ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROA
Imprint
AMG 280
Color
PINK
Shape
CAPSULE
Form
CAPSULE, EXTENDED RELEASE
Labeler
ANI Pharmaceuticals, Inc.
Schedule
CII
NDC
43975-280 ↗ · 2026-06-18

Dosage

Pending medical reviewer

Sources

← Back to the drug index